Evidence map›Paper›PMID 27795842›Full record

ArticleActa naturae

Stem Cells in the Treatment of Insulin-Dependent Diabetes Mellitus.

M A Borisov, O S Petrakova, I G Gvazava, E N Kalistratova, A V Vasiliev

Open access · bronzeAbstract read
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Xenotransplantation - A special case of One Health.One health (Amsterdam, Netherlands) · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

M A BorisovPirogov Russian National Research Medical University, Ostrovitianov str. 1, Moscow, 117997, Russia ; Koltsov Institute of Developmental Biology, Russian Academy of Sciences, Vavilova str. 26, Moscow, 119334, Russia.
O S PetrakovaPirogov Russian National Research Medical University, Ostrovitianov str. 1, Moscow, 117997, Russia ; Lomonosov Moscow State University, Faculty of Biology, Leninskie Gory 1, bld. 12, Moscow, 119991 , Russia.
I G GvazavaPirogov Russian National Research Medical University, Ostrovitianov str. 1, Moscow, 117997, Russia ; Koltsov Institute of Developmental Biology, Russian Academy of Sciences, Vavilova str. 26, Moscow, 119334, Russia.
E N KalistratovaLomonosov Moscow State University, Faculty of Biology, Leninskie Gory 1, bld. 12, Moscow, 119991 , Russia.
A V VasilievLomonosov Moscow State University, Faculty of Biology, Leninskie Gory 1, bld. 12, Moscow, 119991 , Russia ; Koltsov Institute of Developmental Biology, Russian Academy of Sciences, Vavilova str. 26, Moscow, 119334, Russia.
Pirogov Russian National Research Medical University · RUKoltzov Institute of Developmental Biology · RUMoscow State University · TJ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes affects over 350 million people worldwide, with the figure projected to rise to nearly 500 million over the next 20 years, according to the World Health Organization. Insulin-dependent diabetes mellitus (type 1 diabetes) is an endocrine disorder caused by an autoimmune reaction that destroys insulin-producing β-cells in the pancreas, which leads to insulin deficiency. Administration of exogenous insulin remains at the moment the treatment mainstay. This approach helps to regulate blood glucose levels and significantly increases the life expectancy of patients. However, type 1 diabetes is accompanied by long-term complications associated with the systemic nature of the disease and metabolic abnormalities having a profound impact on health. Of greater impact would be a therapeutic approach which would overcome these limitations by better control of blood glucose levels and prevention of acute and chronic complications. The current efforts in the field of regenerative medicine are aimed at finding such an approach. In this review, we discuss the time-honored technique of donor islets of Langerhans transplantation. We also focus on the use of pluripotent stem and committed cells and cellular reprogramming. The molecular mechanisms of pancreatic differentiation are highlighted. Much attention is devoted to the methods of grafts delivery and to the materials used during its creation.

Indexed as

cellular therapydiabetesdifferentiationgene expressionpancreas

Identifiers

PMID27795842
PMCPMC5081704
OpenAlexW2514482674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.